Marian Gorecki
Fondatore presso Valin Technologies Ltd.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Saul Akerib Mashaal | M | 87 |
Pam-Bio Ltd.
 Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel.
Valin Technologies Ltd.
| 30 anni |
| Lean Guat Lim | F | - | 14 anni | |
| Yaron Meyer | M | 45 | 11 anni | |
| Stephen Wills | M | 67 | 7 anni | |
| Smadar Nestor | F | - | 16 anni | |
| Abd Al-Roof Higazi | M | - |
Pam-Bio Ltd.
Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | 10 anni |
| Yehuda Zelig | M | - |
Valin Technologies Ltd.
| - |
| Ofer Gonen | M | 50 | 21 anni | |
| Nuha Higazi | M | - |
Pam-Bio Ltd.
Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | 10 anni |
| Vickie R. Driver | M | 70 | 7 anni | |
| Steve Schaeffer | M | 73 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 15 anni |
| Eilon Asculai | M | - | 17 anni | |
| Zohar Gendler | M | - |
Pam-Bio Ltd.
Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | 9 anni |
| Steven Rubin | M | 63 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 11 anni |
| Liza Domingo | F | - | 16 anni | |
| John Paul Waymack | M | 71 |
Pam-Bio Ltd.
Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | - |
| Keren David-Zarbiv | F | - | 11 anni | |
| Ety Klinger | M | 62 | 10 anni | |
| Roni Solomon | F | - | 18 anni | |
| Yuntao Zhang | M | - |
Valin Technologies Ltd.
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Peter L. Coker | M | 81 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Sharon Malka | F | 51 | - | |
| Avri Havron | M | 76 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 12 anni |
| Lior Rosenberg | M | 78 | 23 anni | |
| Adam Tomasz Polonek | M | 47 | 10 anni | |
| Phillip Frost | M | 87 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 anni |
| Sharon Kochan | F | 55 | - | |
| Ruben Krupik | M | 72 | 13 anni | |
| Slawomir Ziegert | M | 58 | - | |
| Jane Hsaio | M | 77 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 anni |
| Udi Eyal Fima | M | 60 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Meron Mann | M | 72 | 10 anni | |
| Shai Novik | M | 58 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 13 anni |
| Gal Cohen | M | 51 | 13 anni | |
| Nissim Mashiach | M | 63 | - | |
| Aharon Yaari | M | 72 | 2 anni | |
| David Hochman | M | 48 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 anni |
| Adam Stern | M | 60 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Ryszard Krzysztof Krauze | M | 68 | 2 anni | |
| Gil Barzilay | M | - | - | |
| David M. Mashaal | M | - | - | |
| Nirit Freikorn | F | 50 | - | |
| Sigal Aviel | M | 60 | 1 anni | |
| Carsten Henke | M | 58 | 6 anni | |
| Amol Shah | M | 59 | 5 anni | |
| Roland Frösing | M | 64 | 7 anni | |
| Joanna Szymañska-Bulska | F | 60 | 6 anni | |
| G. Balasubramaniam | M | - | - | |
| Yossi Tsuria | M | - |
Weizmann Institute of Science
| 2 anni |
| Mateusz Patryk Kosecki | M | 50 | 9 anni | |
| Joel Kanter | M | 67 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Marcin Dukaczewski | M | 46 | 8 anni | |
| Avner Rotman | M | 80 |
Weizmann Institute of Science
| 3 anni |
| Cohava Gelber | M | 66 |
Weizmann Institute of Science
| 3 anni |
| Robert F. Mauer | M | - |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 1 anni |
| Sarit Firon | F | 58 | 3 anni | |
| Ronit Bendori | M | - |
Weizmann Institute of Science
| 5 anni |
| Alastair Clemow | M | 72 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 2 anni |
| Eugene Bauer | M | 81 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Martin Cooper | M | 58 | 5 anni | |
| Yaron Shoham | M | - | 7 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Israele | 49 | 80.33% |
| Singapore | 13 | 21.31% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Marian Gorecki
- Contatti personali